Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iCasp9-IL15-CD19-CAR NK cells
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
This investigational cell therapy, developed by M.D. Anderson Cancer Center, consists of natural killer (NK) cells derived from umbilical cord blood and genetically engineered via retroviral transduction. The cells express a chimeric antigen receptor (CAR) targeting CD19, incorporating CD28 and CD3-zeta signaling domains to trigger cytotoxicity against B-cell malignancies. To improve the limited persistence typically seen with NK cells, the construct includes the gene for interleukin-15 (IL-15), providing autocrine support for cell survival and proliferation. Additionally, it features an inducible caspase-9 (iCasp9) suicide gene as a safety mechanism, allowing for the rapid elimination of the cells in the event of severe adverse effects. It is primarily being evaluated in Phase I/II clinical trials for the treatment of B-cell lymphomas and leukemias, often in combination with high-dose chemotherapy and autologous stem cell transplantation.
- Other names
- Cord blood-derived CAR-NK cellsCD19-targeted CAR-NK cellsCD-19-targeted CAR-NK cellsCD 19-targeted CAR-NK cellsCAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells
02
Targets
CD19 (B lymphocyte antigen CD19)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)iCasp9 (Inducible caspase-9)
Beyond the preview
Go deeper on iCasp9-IL15-CD19-CAR NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iCasp9-IL15-CD19-CAR NK cells.